or
forgot password

A Phase II Study of the mTOR Inhibitor, CCI-779 in Patients With Advanced Non-Small Cell Lung Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

Thank you

Trial Information

A Phase II Study of the mTOR Inhibitor, CCI-779 in Patients With Advanced Non-Small Cell Lung Cancer


OBJECTIVES: Primary I. Determine the response rate in patients with stage IIIB (with pleural
effusion) or IV non-small cell lung cancer treated with CCI-779.

II. Determine the clinical toxic effects of this drug in these patients.

Secondary I. Determine the 24-week progression-free survival rate in patients treated with
this drug.

II. Determine the time to progression and overall survival of patients treated with this
drug.

III. Evaluate predictive markers of activity (e.g., PTEN mutations and phosphoAkt
expression) of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every
28 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 6 months for up to 5 years.

PROJECTED ACCRUAL: A total of 25-55 patients will be accrued for this study within 12
months.


Inclusion Criteria:



- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

- Stage IIIB (with pleural effusion) or IV disease

- Measurable disease

- At least 1 lesion ≥ 2.0 cm by conventional techniques OR ≥ 1.0 cm by spiral CT
scan

- The following are not considered measurable disease:

- Bone lesions

- Leptomeningeal disease

- Ascites

- Pleural/pericardial effusion

- Inflammatory breast disease

- Lymphangitis cutis/pulmonis

- Cystic lesions

- Abdominal masses that are not confirmed and followed by imaging techniques

- Blood and tissue blocks available

- Must have accessible tumor (i.e., superficial lesions such as lymph node,
subcutaneous nodules) to provide core needle biopsy tissue before and during study
treatment

- No known brain metastases

- Performance status - ECOG 0-2

- At least 12 weeks

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 10 g/dL

- Bilirubin ≤ 2 times upper limit of normal (ULN)

- AST ≤ 3 times ULN (5 times ULN if hepatic metastases are present)

- Creatinine ≤ 1.5 times ULN

- Serum fasting cholesterol ≤ 350 mg/dL

- Serum fasting triglycerides ≤ 400 mg/dL

- HIV negative

- No uncontrolled infection

- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer or non-invasive carcinomas

- No concurrent severe underlying disease that would preclude study participation

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 3 months after study
treatment

- No prior biologic therapy

- No prior gene therapy

- No prior immunotherapy

- No concurrent immunotherapy

- No concurrent prophylactic growth factors to support neutrophil count

- No prior chemotherapy for NSCLC except low-dose cisplatin as a radiosensitizer

- No other concurrent chemotherapy

- No concurrent dexamethasone (10 mg IV)

- No prior radiotherapy to 30% or more of bone marrow

- Concurrent radiotherapy for underlying malignancy and non-target sites (e.g., painful
pre-existing bony metastasis) allowed

- No other concurrent investigational therapy

- No concurrent immunosuppressive therapy

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Confirmed tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST)

Outcome Description:

Confidence intervals for the true success proportion will be calculated using the Duffy-Santner approach.

Outcome Time Frame:

Up to 5 years

Safety Issue:

No

Principal Investigator

Alex Adjei

Investigator Role:

Principal Investigator

Investigator Affiliation:

North Central Cancer Treatment Group

Authority:

United States: Food and Drug Administration

Study ID:

NCI-2012-01810

NCT ID:

NCT00079235

Start Date:

February 2004

Completion Date:

Related Keywords:

  • Recurrent Non-Small Cell Lung Cancer
  • Stage IIIB Non-Small Cell Lung Cancer
  • Stage IV Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Pleural Effusion

Name

Location
North Central Cancer Treatment Group Rochester, Minnesota  55905